Business Context and Reporting Period
This Form 8-K is a current report filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc., as indicated in the metadata) on July 8, 2014. The filing discloses the appointment of a new director to the Board of Directors effective July 8, 2014.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change is the appointment of Dr. Mark Goldberg, M.D., as a Class III director and a member of the Nominating and Corporate Governance Committee. His term is set to expire at the 2017 annual meeting of stockholders.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the compensatory arrangements for the new director:
- Stock Options: Granted a nonqualified stock option to purchase 15,401 shares at an exercise price of $8.86 per share. These options vest on the last day of his initial term (2017 annual meeting).
- Future Grants: Entitled to an additional option for 7,700 shares at each subsequent annual meeting if his term continues, vesting over one year.
- Cash Retainers: $30,000 annual retainer for board service and $3,000 annual retainer for committee service.
- Background: Dr. Goldberg is a board-certified medical oncologist and hematologist with prior executive roles at Synageva BioPharma Corp. and Genzyme Corporation.
Investor Verification Checklist
- Verify the correct registrant name is GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Confirm the stock price of $8.86 on July 8, 2014, to validate the option exercise price.
- Review the press release dated July 10, 2014 (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings to confirm Dr. Goldberg's continued service and any additional option grants.